However, among stage I patients, those with LVSI had a significantly lower proportion of tumor-infiltrating CD28+PD1−/CD8+ T cells compared to those without LVSI (3.54% vs. 11.66%, p = 0.023) (Figure 3C). The gene discussed is CD28; the disease is neoplasm.